{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:55:27Z","timestamp":1789761327800,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81770766"],"award-info":[{"award-number":["No. 81770766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Key Research and Development Program of China","award":["No. 2016YFC0901501"],"award-info":[{"award-number":["No. 2016YFC0901501"]}]},{"name":"the Key Social Development Program of Science and Technology Commission of Shenyang of China","award":["No. F16-206-9-04"],"award-info":[{"award-number":["No. F16-206-9-04"]}]},{"name":"the Key Social Development Program of Science and Technology Commission of Liaoning Province of China","award":["No. 20170540999"],"award-info":[{"award-number":["No. 20170540999"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>It is controversial for the effect and safety between cinacalcet and other treatments in treating secondary hyperparathyroidism for patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Embase, PubMed, and Cochrane Library were searched through Feb 2017. 21 randomized controlled trials were included. We calculated the pooled mean difference (MD), relative risk (RR) and corresponding 95% confidence interval (CI).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Result<\/jats:title>\n<jats:p>Patients received calcimimetic agents had significantly decreased serum parathyroid hormone (MD\u2009=\u2009\u2212\u2009259.24\u2009pg\/mL, 95% CI: \u2212\u2009336.23 to \u2212\u2009182.25), calcium (MD\u2009=\u2009\u2212\u20090.92\u2009mg\/dL, 95% CI: \u2212\u20090.98 to \u2212\u20090.85) and calcium phosphorus product (MD\u2009=\u2009\u2212\u20095.97\u2009mg<jats:sup>2<\/jats:sup>\/dL<jats:sup>2<\/jats:sup>, 95% CI: \u2212\u20099.77 to \u2212\u20092.16) concentration compared with control treatment. However, the differences in cardiovascular mortality and all-cause mortality between calcimimetics agents and control group were not statistically significant. The incidence of nausea (RR\u2009=\u20092.13, 95% CI: 1.62 to 2.79), vomiting (RR\u2009=\u20091.99, 95% CI: 1.78 to 2.23) and hypocalcemia (RR\u2009=\u200910.10, 95% CI: 7.60 to 13.43) in CKD patients with calcimimetics agents was significantly higher than that with control treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Cinacalcet improved the biochemical parameters in CKD patients, but did not improve all-cause mortality and cardiovascular mortality. Moreover, cinacalcet can cause some adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-019-1639-9","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T09:03:44Z","timestamp":1596186224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yiting","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"issue":"2","key":"1639_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1639_CR2","doi-asserted-by":"crossref","unstructured":"Coburn JW. An update on vitamin D as related to nephrology practice: 2003, Kidney. Int Suppl. 2003;(87):S125\u201330.","DOI":"10.1046\/j.1523-1755.64.s87.19.x"},{"issue":"6455","key":"1639_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/366575a0","volume":"366","author":"EM Brown","year":"1993","unstructured":"Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575\u201380.","journal-title":"Nature"},{"issue":"15","key":"1639_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516\u201325.","journal-title":"N Engl J Med"},{"issue":"2","key":"1639_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308(2):627\u201335.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1639_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","volume":"58","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000;58(1):436\u201345.","journal-title":"Kidney Int"},{"issue":"4","key":"1639_CR7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","volume":"13","author":"WG Goodman","year":"2002","unstructured":"Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13(4):1017\u201324.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1639_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","volume":"63","author":"JS Lindberg","year":"2003","unstructured":"Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63(1):248\u201354.","journal-title":"Kidney Int"},{"issue":"3","key":"1639_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","volume":"14","author":"LD Quarles","year":"2003","unstructured":"Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14(3):575\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1639_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","volume":"46","author":"C Charytan","year":"2005","unstructured":"Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46(1):58\u201367.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1639_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1639_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1744-9987.2008.00556.x","volume":"12","author":"T Akiba","year":"2008","unstructured":"Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2008;12(2):117\u201325.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"1639_CR13","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3(6):1718\u201325.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1639_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23(1):328\u201335.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1639_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1639_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2008.09.021","volume":"53","author":"M Chonchol","year":"2009","unstructured":"Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197\u2013207.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1639_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1744-9987.2011.00994.x","volume":"15","author":"EM El-Shafey","year":"2011","unstructured":"El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial. 2011;15(6):547\u201355.","journal-title":"Ther Apher Dial"},{"issue":"4","key":"1639_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327\u201339.","journal-title":"Nephrol Dial Transplant"},{"issue":"26","key":"1639_CR19","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"1639_CR20","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27(8):3270\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1639_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2369-14-112","volume":"14","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim H, Shin N, Na KY, Kim YL, Kim D, et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol. 2013;14:112.","journal-title":"BMC Nephrol"},{"issue":"5","key":"1639_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/ndt\/gfs568","volume":"28","author":"P Urena-Torres","year":"2013","unstructured":"Urena-Torres P, Bridges I, Christiano C, Cournoyer SH, Cooper K, Farouk M, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28(5):1241\u201354.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1639_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, Block GA. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31(5):943\u201352.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1639_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al. A randomized trial of Cinacalcet versus vitamin D analogs as Monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015;10(6):1031\u201340.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1639_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/hdi.12410","volume":"20","author":"C Mei","year":"2016","unstructured":"Mei C, Chen N, Ding X, Yu X, Wang L, Qian J, et al. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Hemodial Int. 2016;20(4):589\u2013600.","journal-title":"Hemodial Int"},{"issue":"7","key":"1639_CR26","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"1639_CR27","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.","journal-title":"Bmj"},{"issue":"4","key":"1639_CR28","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 2013;10(4):e1001436.","journal-title":"PLoS Med"},{"issue":"6","key":"1639_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3109\/0886022X.2016.1172468","volume":"38","author":"N Sekercioglu","year":"2016","unstructured":"Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes LC, et al. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2016;38(6):857\u201374.","journal-title":"Ren Fail"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-019-1639-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:37:17Z","timestamp":1627688237000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1639-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1639-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"28 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}